DEF: Silexion Seeks Shareholder Approval to Boost Capital for Nasdaq Compliance and Growth

Silexion Therapeutics Corp. is seeking shareholder approval to significantly increase its authorized share capital to meet Nasdaq listing requirements and fund the development of its RNAi therapies.

Summary

• Silexion Therapeutics Corp. is holding an extraordinary general meeting on August 12, 2025, to approve an increase in its authorized share capital.
• The current authorized share capital is US$20,000, divided into 1,481,482 ordinary shares of US$0.0135 par value each, following a 1-for-15 reverse share split effective July 29, 2025.
• The company proposes to increase the authorized share capital to US$121,500, divided into 9,000,000 ordinary shares of US$0.0135 par value each.
• The primary purpose of this increase is to enable the company to achieve and maintain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of shareholders' equity by September 19, 2025.
• The increased capital is also needed for basic financing needs of operations and potential business development transactions, particularly for the pre-clinical and clinical development of innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations.
• Currently, Silexion has only 529,302 available, unissued ordinary shares, which is deemed insufficient for its goals.
• The proposed enhanced authorized share capital is expected to suffice for the company's objectives at least through the end of 2026.

Sentiment

Score: 6

Explanation: The filing addresses a critical issue (Nasdaq listing compliance) and outlines a necessary step for the company's continued operation and strategic development. While the potential for significant dilution is a negative, the alternative (delisting) would be far worse. The proactive approach to secure funding for RNAi therapy development is positive, but the inherent dilution and market price risk temper the overall sentiment. It's a necessary but not inherently "good news" event, more of a "problem-solving" event.

Positives

• Maintaining Nasdaq listing enhances the price, liquidity, and trading market for the company's securities, which is critical for shareholder value.
• The increased capital will enable funding for the pre-clinical and clinical development of innovative RNAi therapies for solid tumors driven by KRAS mutations, addressing a significant medical need.
• Provides transactional flexibility for potential value-enhancing business development opportunities and the acquisition of complementary assets.
• Allows the company to continue incentivizing employees, officers, and directors through equity grants, aligning their interests with shareholders.
• The Board of Directors unanimously recommends a vote FOR the Authorized Share Capital Increase Proposal, indicating strong internal support.

Negatives

• Future issuance of a significant number of ordinary shares will cause substantial dilution to existing shareholders' percentage holdings and voting power.
• The issuance of additional shares could result in a drop in the trading price per share of ordinary shares.
• Anticipation of future issuances and resales may make it more difficult for the company to sell equity or equity-related securities at a favorable time and price.
• Depending on the consideration received, future issuance transactions could reduce shareholders' equity on a per-share basis.

Risks

• Substantial dilution to existing shareholders and reduction in their voting power due to the potential issuance of a significant number of additional ordinary shares.
• Decline in the trading price of ordinary shares may occur as a result of future issuances and resales of newly available shares.
• Anticipation of future issuances and resales could make it more difficult for the company to sell equity or equity-related securities in the future at a desirable price.
• The newly available authorized shares could, in theory, be used as an anti-takeover device, potentially limiting opportunities for shareholders to dispose of their ordinary shares at a premium.
• Failure to approve the Authorized Share Capital Increase Proposal will result in the company not having enough ordinary shares available to achieve Nasdaq listing compliance, leading to the delisting of its ordinary shares and warrants in the near future.

Future Outlook

The company expects the increased authorized share capital to enable it to restore and maintain Nasdaq listing compliance, continue progress with pre-clinical and clinical programs for RNAi therapies, and pursue potential complementary business development opportunities for shareholder value creation through the end of 2026. Future equity issuances are anticipated to fund operations and meet Nasdaq requirements.

Management Comments

• "Our Nasdaq listing is a critical asset of our company and our shareholders, as it enhances the price and liquidity of, and the trading market for, our securities, and it is therefore in the best interest of our shareholders that we preserve it."
• "We intend to be as selective as possible before issuing share capital, to ensure that the terms of transactions in which we issue shares are consistent with our strategic goal of supporting value enhancement for our shareholders and buttressing the price of our ordinary shares."
• "We will carefully manage our enhanced authorized share capital to support and reinforce, as much as possible, the price and liquidity of, and the trading market for, our traded securities."
• "The Board unanimously recommends a vote FOR the proposed increase to the authorized share capital of the Company pursuant to the Authorized Share Capital Increase Proposal."

Industry Context

Silexion Therapeutics is focused on developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, a significant area of unmet medical need in oncology. The need for substantial funding and transactional flexibility for pre-clinical and clinical development is typical for biotech companies in this phase, and maintaining a Nasdaq listing is crucial for accessing capital in the competitive biotech funding landscape.

Comparison to Industry Standards

• The Nasdaq Capital Market's $2.5 million shareholders' equity requirement is a standard listing criterion for smaller growth companies in the biotech sector.
• The necessity for increased authorized share capital to facilitate equity raises is a common practice for biotech companies undergoing significant research and development, similar to how other clinical-stage oncology companies would raise capital in their early stages.
• The 1-for-15 reverse share split is a common corporate action taken by companies to meet minimum bid price requirements for continued listing on exchanges like Nasdaq.

Corporate Governance

Legal Proceedings

• The company successfully appealed a Nasdaq delisting notice, receiving a favorable decision from a Nasdaq hearings panel on July 7, 2025, allowing it to remain listed on the Nasdaq Capital Market subject to meeting specific conditions, including the $2.5 million shareholders' equity requirement.

Related Party Transactions

• A convertible promissory note was issued to the sponsor of Moringa (with which Silexion completed a business combination in August 2024), with the number of underlying shares dependent on fluctuating market prices or financing transaction prices.
• Shares were issued to Moringa Sponsor, LP and Greenstar, L.P. (PIPE Investor) in connection with the business combination and a PIPE financing.
• Shares are held by Guangzhou Sino-Israel Biotech Fund (GIBF) related to the transfer of its noncontrolling interest in Silenseed (China) Ltd. and fully-vested RSUs granted for director services provided by Avner Lushi and Shlomo Noy on behalf of GIBF.

Stakeholder Impact

• Shareholders face potential significant dilution of their percentage holdings, reduction in voting power, and a possible drop in share price due to future equity issuances. However, maintaining the Nasdaq listing is crucial for liquidity and market access, which is in their long-term interest.
• Employees and directors will continue to be incentivized through equity grants, aligning their interests with the company's performance.
• Creditors, particularly the Moringa sponsor holding a convertible promissory note, may see their debt converted into equity, impacting the company's capital structure.

Next Steps

• Shareholders are to vote on the Authorized Share Capital Increase Proposal at the Extraordinary General Meeting on August 12, 2025.
• If the proposal is approved, the company will proceed with issuing equity securities to achieve and maintain $2.5 million shareholders' equity by September 19, 2025.
• Continue pre-clinical and clinical development of RNAi therapies to treat solid tumors driven by KRAS mutations.
• Explore potential business development transactions for complementary assets.
• Manage the enlarged authorized share capital to reinforce the price and liquidity of traded securities.

Key Dates

Recommendation

The filing addresses a critical requirement for Silexion to maintain its Nasdaq listing, which is essential for its long-term viability and access to capital. While the proposed increase in authorized share capital is a necessary step, it explicitly signals significant future dilution for existing shareholders, which will likely depress the share price. The company's focus on RNAi therapies for KRAS mutations is a high-potential area, but it is still in pre-clinical and clinical development, implying substantial future funding needs and inherent risks. Given the immediate dilution risk balanced against the necessity of maintaining listing and pursuing R&D, a "hold" recommendation is appropriate. Investors should monitor the actual terms and timing of future capital raises and the progress of their clinical programs.

Keywords

Silexion Therapeutics, SEC filing, DEF 14A, proxy statement, authorized share capital, Nasdaq listing, Nasdaq Capital Market, shareholder equity, RNAi therapies, KRAS mutations, pre-clinical development, clinical development, business development, share dilution, reverse share split, corporate governance, capital raise, biotech, pharmaceuticals, oncology